Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients

作     者：Machuca, A Gutierrez, M Mur, A Soriano, V 

作者机构：Hosp Mar Serv Pediat Barcelona Spain Inst Salud Carlos III Infect Dis Serv Madrid Spain 

出 版 物：《ANTIVIRAL THERAPY》 (Antiviral Ther.)

年 卷 期：1998年第3卷第3期

页      面：187-189页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 10[医学] 

主　　题：获得性免疫缺陷综合征/药物疗法 获得性免疫缺陷综合征/免疫学 获得性免疫缺陷综合征/病毒学 抗HIV药/治疗应用 CD4淋巴细胞计数 HIV核心蛋白质p24/血液 HIV-1/分类 青少年 成年人 女(雌)性 人类 男(雄)性 中年人 

摘      要：Failure to recognize infection caused by human immunodeficiency virus type 1 (HIV-1) group O Variants has been described using both serological and genetic techniques. Moreover, the monitoring of response to antiretroviral therapy is difficult in persons carrying this infection since most currently available tests for quantifying Viral load are not reliable for group O viruses. Considering the low level of divergence between the p24 proteins of group M and O viruses, we have examined whether the quantification of circulating p24 antigenaemia might be used as a surrogate marker of response to therapy in three subjects with HIV-1 group O infection treated with antiretroviral drugs. In summary, all three patients showed a significant decline in circulating plasma p24 antigenaemia, although only one achieved undetectable levels. The decline in p24 antigenaemia was parallel to an increase in the CD4 count and was associated with an improvement in clinical status.